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oninvasive Etiologic Diagnosis of Cardiac
myloidosis Using 99mTc-3,3-Diphosphono-
,2-Propanodicarboxylic Acid Scintigraphy
nrica Perugini, MD,* Pier Luigi Guidalotti, MD,† Fabrizio Salvi, MD,‡ Robin M. T. Cooke, MA,*
inzia Pettinato, MD,† Letizia Riva, MD,* Ornella Leone, MD,§ Mohsen Farsad, MD,†
aolo Ciliberti, MD,* Letizia Bacchi-Reggiani, MSC, MBIOSTAT,* Francesco Fallani, MD,*
ngelo Branzi, MD,* Claudio Rapezzi, MD*
ologna, Italy
OBJECTIVES We investigated the diagnostic accuracy of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic
acid (99mTc-DPD) scintigraphy for differentiation of monoclonal immunoglobulin light-
chain (AL) and transthyretin (TTR)-related cardiac amyloidosis.
BACKGROUND Differential diagnosis between TTR-related and AL amyloidosis is often complex and
time-consuming.
METHODS Patients under routine observation with TTR-related/AL systemic amyloidosis and echocar-
diographic evidence of cardiac involvement were studied with 99mTc-DPD scintigraphy.
RESULTS Patients with cardiac involvement of TTR-related (group A; n  15) and AL (group B; n 
10) etiology were comparable for left ventricular mass and renal function. Heart and
heart/whole-body tracer retention were significantly higher (p  0.05) in group A as
compared with group B and with 10 unaffected controls. At visual scoring, cardiac
99mTc-DPD uptake was present in all group A patients and absent in all group B patients;
thus, using genotyping/immunohistochemistry as the reference technique, the accuracy of
99mTc-DPD scintigraphy for distinction of TTR-related and AL etiology was 100%. Cardiac
99mTc-DPD uptake was also absent among unaffected controls. Using echocardiography as
the reference standard for recognition of cardiac involvement, sensitivity and specificity of
scintigraphy were both 100% for group A patients; in group B, sensitivity was 0% and
specificity was 100% (accuracy, 50%). Eleven patients with myocardial 99mTc-DPD uptake
underwent 99mTc-methylene diphosphonate (99mTc-MDP) scintigraphy; all patients showed
a 99mTc-MDP myocardial visual score of 0.
CONCLUSIONS Etiology is a third major cause—in addition to type of organ-involved (soft-tissue/heart) and
tracer type—of scintigraphic variability in cardiac amyloidosis. This is a highly relevant
consideration for future studies. We conclude that 99mTc-DPD scintigraphy is a useful step
in the workup of the differential diagnosis of TTR versus AL etiology in patients with
documented cardiac amyloidosis. (J Am Coll Cardiol 2005;46:1076–84) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.073American College of Cardiology Foundation
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iardiac involvement has major clinical and prognostic
mplications in amyloidosis. Acquired monoclonal immu-
oglobulin light-chain (AL) and transthyretin (TTR)-
elated (familial and wild-type/senile) disease are the most
requent causes of cardiac amyloidosis (1). In hereditary
myloidosis, cardiac involvement can limit short-term and
ong-term results of orthotopic liver transplantation (OLT)
2,3) and influence decisions to perform combined heart-
iver transplantation (4). Severe cardiac involvement in AL
myloidosis can limit optimal hematologic treatments, in-
luding bone marrow transplantation (5).
Differential diagnosis between TTR-related and AL
myloidosis is often complex and time-consuming. Echo-
ardiography is considered the gold standard for noninva-
From the *Institute of Cardiology, †Nuclear Medicine Unit, and §Department of
athology, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy;
nd the ‡Department of Neurology, Ospedale Bellaria, Bologna, Italy.a
Manuscript received March 4, 2005; revised manuscript received May 18, 2005,
ccepted May 24, 2005.ive diagnosis of amyloidotic cardiomyopathy (1,6), but it is
ot etiologically informative. A recent study showed a 10%
isdiagnosis rate between familial and AL amyloidosis (7).
lthough genotyping and/or immunohistochemical analysis
re mandatory for a definitive diagnosis, they are not routine
xaminations and thus require accurate patient selection
7,8).
Various tracers (mainly phosphonates) have been used in
he past for scintigraphic assessment of cardiac amyloidosis,
nd they have produced heterogeneous results (9–22).
hese discrepancies might partially be explained by the
ariable composition of the amyloid substance (14,17). We
ypothesized that this apparent limit might translate into a
oninvasive tool for diagnostic evaluation of etiology. In this
ilot study, we investigated the uptake of 99mTc-3,3-
iphosphono-1,2-propanodicarboxylic acid (99mTc-DPD)
n a population of patients with TTR-related or AL cardiac
myloidosis. The main goal of the study was to assess the
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September 20, 2005:1076–84 Etiologic Diagnosis of Cardiac Amyloidosisiagnostic accuracy and predictive value of 99mTc-DPD
cintigraphy for differentiation of TTR-related and AL
ardiac amyloidosis using genotyping/immunohistochemis-
ry as a reference standard. Subsidiary goals were to explore
atterns of myocardial and soft-tissue DPD uptake and
elationships between scintigraphic and echocardiographic/
istologic findings.
ETHODS
tudy design and selection criteria. All patients under
outine observation in our cardiology and neurology units
etween January 2004 and January 2005 with a diagnosis of
TR-related or AL amyloidosis with echocardiographically
emonstrated cardiac involvement were enrolled in this
tudy (no exclusion criteria were applied). External controls
ere 10 unaffected patients (6 men, 4 women; median age,
8 years; age range, 55 to 74 years) undergoing scintigraphy
or oncologic reasons. All participants provided informed
onsent for participation. Ethical approval was not required
or this noninvasive study.
iagnostic definitions. Diagnosis of amyloidosis was de-
ned by histologic documentation of Congo-red staining
nd apple-green birefringence under cross-polarized light in
t least one involved organ (1). Cardiac involvement was
chocardiographically defined as end-diastolic thickness of
he interventricular septum 1.2 cm (in the absence of any
ther cause of ventricular hypertrophy) plus two or more of
he following features: 1) homogeneous atrioventricular
alve thickening; 2) atrial septal thickening; and 3) sparkling
ppearance of the ventricular septum (6). A clear-cut dis-
inction between TTR-related and AL amyloidosis was
ased on genotyping and/or immunohistochemistry (7).
iagnosis of familial TTR-related amyloidosis was defined
y a documented TTR mutation at DNA analysis; TTR-
elated wild-type (senile) amyloidosis by positive immuno-
istochemistry for TTR in the absence of any TTR muta-
ion at DNA analysis (23). Monoclonal immunoglobulin
ight-chain amyloidosis was diagnosed by the presence of
onoclonal plasma cells in the bone marrow, plus: 1)
egative immunohistochemistry for TTR, and 2) absence of
Abbreviations and Acronyms
AL  monoclonal immunoglobulin light-chain
CA  cardiac amyloidosis
LV  left ventricle/ventricular
OLT  orthotopic liver transplantation
ROI  region of interest
SPECT  single-photon emission computed
tomography
99mTc-DPD  99mTc-3,3-diphosphono-1,2-propano-
dicarboxylic acid
99mTc-MDP  99mTc-methylene diphosphonate
TTR  transthyretinny TTR mutation at DNA analysis (7). lenotyping/immunohistochemistry and histology. For
enotyping, DNA was isolated from peripheral blood and
xons 2, 3, and 4 of the TTR gene (accession number
11844) were amplified by polymerase chain reaction
Takara ExTaq polymerase, TaKaRa Shuzo, Otsu, Japan)
y using primers previously described (24). Amplified DNA
ragments were directly sequenced by using an ABI Prism
100 automated sequencer (Applied Biosystems, Foster
ity, California).
Endomyocardial biopsies were microwave fixed/
rocessed, and multiple 2-m sections were tested for the
resence of amyloid by Congo-red staining and apple-green
irefringence under cross-polarized light microscopy.
mounts of amyloid deposits were semiquantitatively clas-
ified as mild (30% involvement of the tissue fragments),
oderate (30% to 60% involvement), or severe (60%
nvolvement) (25). Immunohistochemical analysis was per-
ormed by the Labeled StreptAvidin Biotin (LSAB)
ethod using an antibody against TTR (R. P. Linke, Max
lank Institute of Biochemistry, Martinsried, Germany).
cintigraphy protocol and image analysis. Scintigraphy
as always performed 2 months after echocardiography
nd genotyping/immunohistochemistry. All patients re-
eived 740 MBq of 99mTc-DPD intravenously; a dual-head
amera (ECAM, Siemens Medical Systems, Hoffman Es-
ates, Illinois) equipped with low-energy, high-resolution
ollimators was used. Whole body scans were obtained five
inutes (early) and three hours (late) after injection. In
atients showing cardiac uptake, a myocardial single-
hoton emission computed tomography (SPECT) study
as acquired after the late whole-body scan. Image analysis
as independently performed by three experienced analysts
P.G., C.P., and M.F.) blinded to all patient data (any
isagreement was settled by group discussion). Visual scor-
ng of cardiac retention was routine (i.e., score 0, absent
ardiac uptake and normal bone uptake; score 1, mild
ardiac uptake, inferior to bone uptake; score 2, moderate
ardiac uptake accompanied by attenuated bone uptake;
core 3, strong cardiac uptake with mild/absent bone up-
ake). Semiquantitative analysis of heart retention, whole-
ody retention, and heart/whole-body ratio were evaluated
rom region of interest (ROI) drawings in the standard
anner. In brief, on anterior images rectangular ROIs were
rawn over the heart, and irregular ROIs over the kidneys
nd bladder. These ROIs were copied and mirrored on
osterior images, and for each ROI geometric means of the
wo projections were calculated. All ROIs were corrected for
ackground counts. Total counts in the images were con-
idered as whole-body counts. Early whole-body counts
ere used to represent the injected activity. Whole-body
etention was evaluated by comparing counts in the late
mages (corrected for decay and scan speed, and subtracting
he activity in the urinary tract and bladder) with the counts
n the early whole-body images. Heart retention was eval-
ated by comparing decay-corrected counts of the heart in
ate images with counts in early whole-body images. Heart/
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Etiologic Diagnosis of Cardiac Amyloidosis September 20, 2005:1076–84hole-body ratios were calculated by dividing counts in the
eart by counts in late whole-body images. Soft tissue
ptake (particularly skeletal muscle and splanchnic organs)
as also visually assessed using an analogous scoring system
o that used for the heart.
Patients showing cardiac uptake of 99mTc-DPD were
nvited to receive 99mTc-methylene diphosphonate (99mTc-
DP) scintigraphy using the same protocol and heart and
oft-tissue visual scoring systems.
tatistical analysis. Statistical analysis was performed us-
ng SPSS 11.0 statistical software (SPSS Inc., Chicago,
llinois). Continuous variables are expressed as median
interquartile range), categorical variables as percentages.
hen comparing subgroups, the Fisher exact test or con-
ingency tables were used (the former when the expected
requency of counts in at least one cell of 2  2 tables was
5), alongside the Mann-Whitney U or the Kruskal-Wallis
est. For multiple comparisons, the Dunn test was also
pplied. Any p values 0.05 were considered statistically
ignificant.
ESULTS
atient population. Twenty-five cardiac amyloidosis pa-
ients were enrolled, all of whom completed the study
rotocol. Table 1 summarizes the principal clinical, electro-
ardiographic, and echocardiographic findings in the patient
opulation, subdivided into two groups according to etiol-
gy. Of the 15 patients with TTR-related amyloidosis with
ardiac involvement (group A), 10 had familial TTR amy-
oidosis (carrying Glu89Gln [n  1], Val30Met [n  2],
Table 1. Clinical, Morphologic and Functiona
Age (yrs)
Median
Interquartile range
NYHA functional class II (% patients)
Neurologic involvement (% patients)
Glomerular filtration rate (ml/min)
Median
Interquartile range
Abnormal electrocardiogram (% patients)
LV mass (g/m2)
Median
Interquartile range
Interventricular septal thickness (mm)
Median
Interquartile range
LV ejection fraction (%)
Median
Interquartile range
Restrictive LV filling pattern at echo-Doppler
(% patients)
AL monoclonal immunoglobulin light-chain; LV  left
transthyretin.la36Pro [n 2], Thr49Ala [n 2], Phe33Val [n 1], or mle68Leu [n  2] TTR mutations), and 5 had senile TTR.
o difference was apparent regarding age, renal function,
nd left ventricular (LV) mass (all p  0.40). None of the
atients had any associated cardiovascular disease, including
ystemic hypertension and coronary artery disease (the latter
as excluded on clinical grounds, as well as by coronary
ngiography in three patients with suspected angina).
cintigraphy findings. Figure 1 shows representative ex-
mples of the spectrum of 99mTc-DPD uptake among
atients and control patients. Semiquantitative and visual
cintigraphic findings are summarized in Figure 2 and Table
, according to the two subgroups of the patient population
nd the unaffected controls. At semiquantitative analysis,
eart tracer retention and heart/whole-body retention ratio
ere both about two-fold higher in group A as compared
ith group B and also with controls (Fig. 2). Smaller
ifferences were also observed between group B and con-
rols, plausibly because of intense mediastinal/sternal uptake
n a single patient in group B (see asterisk in Fig. 2A).
egarding the visual score, myocardial uptake (score 0)
as detected in 15 of 15 (100%) group A patients, as
ompared with 0 of 10 (0%) in group B and 0 of 10 (0%) in
he control group.
We were able to compare the macroscopic, histologic,
nd 99mTc-DPD scintigraphic appearance of myocardium
rom one group A patient who underwent combined heart–
iver transplantation (one month after scintigraphy) and one
roup B patient who died (after three months). Myocardial
ptake of 99mTc-DPD occurred only in the patient with
TR-related amyloidosis, despite similar LV mass and
ameters in the Overall Patient Population
Group A
TR-Related
iac Amyloidosis
15 Patients)
Group B
AL Cardiac
Amyloidosis
(10 Patients) p Value
56 60 0.91
48–76 58–65
13 50 0.075
53 42 0.41
64 66 0.95
47–85 59–80
93 100 1.00
184 170 0.64
160–291.5 136–215
16 15.5 0.69
13.5–20 13–17
53 54 0.77
41–66 45–57
26 66 0.049
icular; NYHA  New York Heart Association; TTR l Par
T
Card
(yocardial infiltration (Fig. 3).
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September 20, 2005:1076–84 Etiologic Diagnosis of Cardiac AmyloidosisEleven patients with myocardial uptake of 99mTc-DPD
greed to undergo 99mTc-MDP scintigraphy. The visual
core for 99mTc-MDP myocardial uptake was 0 in all of
hese patients. A representative example of differences in
yocardial uptake of the two tracers can be seen in Figure
. The visual score for 99mTc-MDP soft tissue uptake was 0
n 8 patients and 1 in the remaining 3.
iagnostic accuracy of 99mTc-DPD scintigraphy for
ifferentiation of TTR-related and AL cardiac amyloid-
sis. We assessed the diagnostic accuracy of 99mTc-DPD
cintigraphy (visual score 0) for differentiation of TTR-
elated and AL cardiac amyloidosis using genotyping/
mmunohistochemistry as the reference technique. Within our
ubpopulation of amyloidosis patients with echocardiographic
vidence of cardiac involvement (groups A and B), sensitivity
nd specificity of 99mTc-DPD scintigraphy were both 100%.
iagnostic accuracy of 99mTc-DPD scintigraphy for
etection of amyloidotic cardiomyopathy within different
tiologic settings. We also considered the diagnostic ac-
uracy of a scintigraphy visual score 0 between each of the
igure 1. Representative examples illustrating the spectrum of 99mTc-3,3-d
ith transthyretin (TTR)-related or monoclonal immunoglobulin light-ch
cans, anterior view; bottom row  cross sectional views of cardiac single
ontrol subject without visually detectable uptake. (B) Patient with AL am
ny visually detectable sign of myocardial 99mTc-DPD uptake; mild uptake
TR-related amyloidosis and echocardiographic documentation of cardiac
one uptake); in one of the patients (D), splanchnic uptake is also visiblewo groups of patients and the control patients for detection df cardiac amyloidosis using echocardiography as the refer-
nce standard. Sensitivity and specificity of scintigraphy
ere both 100% for group A (TTR-related patients). By
ontrast, for group B (AL patients), sensitivity was 0% and
pecificity was 100%. Thus, the overall accuracy for detec-
ion of amyloid of both types was only 50%. These findings
urther illustrate the concept that etiology can be a major
ause of variability in the diagnostic performance of 99mTc-
PD scintigraphy.
atterns of myocardial uptake of 99mTc-DPD. All but
ne of the group A patients had widespread involvement of
ll myocardial segments (Fig. 4A), whereas the remaining
atient showed localized septal accumulation (Fig. 4B).
hese observations paralleled the patterns of increased wall
hickness visible at echocardiography (Fig. 4).
9mTc-DPD scintigraphy findings in soft tissue. Regard-
ng extracardiac uptake of 99mTc-DPD, at semiquantitative
nalysis whole-body retention was significantly higher in
oth groups A and B with respect to controls (Table 2, Fig.
C). The increased uptake of 99mTc-DPD was visually
phono-1,2-propanodicarboxylic acid (99mTc-DPD) uptake among patients
L) cardiac amyloidosis and unaffected controls (top row  whole-body
on emission computed tomography in the same patients). (A) Unaffected
sis and echocardiographic documentation of cardiac involvement without
e tracer is visible only at the soft tissue level. (C and D) Two patients with
ement, both showing strong myocardial 99mTc-DPD uptake (with absentiphos
ain (A
-phot
yloido
of thetectable at the muscular and/or splanchnic level in 13 of
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Etiologic Diagnosis of Cardiac Amyloidosis September 20, 2005:1076–845 group A patients and 5 of 5 group B patients. No
ifference was apparent between groups A and B. The visual
core for 99mTc-MDP soft tissue uptake was 0 in eight
atients and 1 in the remaining three.
elationships between scintigraphic and echocardio-
raphic/histologic findings. We investigated whether the
egree of myocardial 99mTc-DPD uptake as assessed by
igure 2. Comparison of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic
cid heart retention (A), whole-body retention (B), and heart/whole-body
etention ratio (C) between group A patients (transthyretin [TTR]-related
ardiac amyloidosis [CA]), group B patients (monoclonal immunoglobulin
ight-chain [AL] cardiac amyloidosis), and controls. The lower/upper limits of
he boxes indicate 25th/75th percentiles; horizontal lines (and values) within
oxes indicate medians. Values lying more than 1.5 and 3 box-lengths from the
5th percentile are indicated by circles and asterisks, respectively.isual score could be related to LV mass and/or interven- Tricular septal thickness. No evidence of relationships with
V mass or interventricular septal thickness emerged (p 
.54 and p  0.43, respectively, using Kruskal-Wallis test).
s can be seen from Figure 5, the vast majority of patients
ad a similar spectrum of LV masses irrespective of visual
core at scintigraphy.
In myocardial biopsies (available from 8 of 15 group A
atients and all 10 group B patients), the degree of amyloi-
otic infiltration was similar in patients with or without
yocardial 99mTc-DPD uptake (severe infiltration in 5 of 8
s. 7 of 10 patients, respectively; p  0.87).
ISCUSSION
o our knowledge, this is the first assessment of 99mTc-
PD scintigraphy as a potential diagnostic tool for assess-
ent of etiology in cardiac amyloidosis. Our findings could
ave potential clinical implications (especially in the light of
ecent therapeutic advances), and they also could help clarify
he conflicting data in published reports on the use of bone
racers in the scintigraphic evaluation of amyloidosis.
Noninvasive detection of amyloid has been investigated
sing three main groups of radiolabeled tracers: 123I-labeled
erum amyloid P protein (26,27); aprotinin (28,29); and
one tracers, mainly 99mTc-pyrophosphate (9–15) and
9mTc-HDP (20,21). Labeled serum amyloid P protein
ocalizes rapidly and specifically to amyloid deposits (in
roportion to the amount of amyloid) and persists there,
llowing quantitative monitoring of amyloid deposition and
egression during therapy (low quality of heart visualization
nd limited availability are current limitations of this tracer
12,13]). 99mTc-aprotinin (a protease inhibitor) has been
ainly studied in AL patients, in whom it accumulates in
arious organs, including myocardium: available experience
s limited and quantitative assessment is not feasible (14,15).
ata on bone tracers are numerous but heterogeneous.
9mTc-pyrophosphate is the most widely studied: because it
inds avidly to many types of amyloid, it was a popular
maging agent for cardiac amyloidosis during the 1980s.
owever, amyloidotic uptake of this tracer has not been
uantitated, and it has lower diagnostic sensitivity than
chocardiography (2–8,10).
Relatively few studies are available on the diagnostic perfor-
ance of 99mTc-DPD (16,17), 99mTc-methylene diphospho-
ate, or 99mTc-hydroxymethylene-diphosphonate in amyloid-
sis (18–20). The numbers of patients included in these studies
ere often low, and the type of amyloidosis was frequently
nspecified. None of these studies used immunohistochemis-
ry/genotyping to exclude misdiagnosis between TTR and AL
orms. Both positive and negative myocardial uptake of bone
racers has been reported in patients with definite cardiac
myloidosis, generating a confusing scenario.
In the present study, abnormal cardiac uptake of 99mTc-
PD (whether at visual scoring or semiquantitative analy-
is) occurred exclusively in patients with familial or senile
TR-related cardiac amyloidosis, despite quite similar signs
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September 20, 2005:1076–84 Etiologic Diagnosis of Cardiac Amyloidosisf amyloidotic myocardial infiltration in the two groups, as
xpressed by comparable values of interventricular septal
hickness and LV mass. The strength of these findings was
einforced by the use of immunohistochemistry/genotyping
or differentiation between AL and TTR-related amyloid-
sis. The data are broadly in line with the single published
tudy of 99mTc-DPD scintigraphy in a small series of
atients in familial TTR-related cardiac amyloidosis (17).
n the only patient with AL amyloidosis reported in the
iterature to have myocardial uptake of 99mTc-DPD, the
tiologic diagnosis was based only on the presence of
bnormal protein at serum and urine electrophoresis (a
otentially misleading finding) (16).
In our study sample, selective myocardial uptake of
9mTc-DPD provided 100% accuracy for differentiation of
TR-related and AL etiology of cardiac amyloidosis. This
otential diagnostic application is confined to amyloidotic
atients with myocardial involvement and cannot be ex-
ended to patients with involvement limited to soft tissues
nd/or splanchnic organs. Differential diagnosis of TTR-
elated and AL cardiac amyloidosis is often problematic,
specially from the clinical standpoint. Electrocardiographic
nd echocardiographic findings are superimposable, irre-
pective of the composition of the deposits (30,31). Clini-
ally, AL cardiac amyloidosis more often affects older
atients and is associated with a more rapid course with
rominent symptoms of heart failure. However, exceptions
re frequent. For example, patients carrying the TTR
lu89Gln mutation (4) can experience an accelerated
ourse strongly influenced by cardiologic problems. Further-
ore, the first clinical manifestations of amyloidosis can be
ardiologic with a variety of other mutations. A relatively
requent diagnostic pitfall occurs in elderly patients with
onoclonal gammopathy and echocardiographic signs of
ardiac amyloidosis. Because of the high prevalence of subtle
onoclonal gammopathies in the general population, it is
able 2. Scintigraphic Findings in the Patient Population and Co
Group A
TTR-Related CA
(15 Patients)
eart tracer retention (%)
Median 7.3*†
Interquartile range 6.7–8.4
hole-body tracer retention (%)
Median 70.1†
Interquartile range 63.6–77.3
eart/whole-body ratio
Median 10.0*†
Interquartile range 8.9–11.2
isual cardiac score
0 0 (0%)
1 0 (0%)
2 3 (20%)
3 12 (80%)
p  0.05 group A vs. B. †p  0.05 group A vs. control group. ‡p  0.05 group B
CA  cardiac amyloidosis; TTR  transthyretin.ot possible automatically to assume a diagnosis of AL pardiac amyloidosis in such cases (7) (as in one of our
atients with TTR-related cardiac amyloidosis casually
ssociated with a monoclonal gammopathy). Despite these
bstacles, a correct differential diagnosis of TTR-related
nd AL cardiac amyloidosis is now mandatory in the light of
he availability of highly specific therapeutic options: OLT
r combined heart-liver transplantation for familial TTR
2–4); high-dose chemotherapy and bone marrow trans-
lantation for AL amyloidosis (5). Moreover, definite diag-
osis of a hereditary TTR form enables appropriate genetic
ounseling.
Regarding our wider understanding of the conflicting
cintigraphic data available on amyloidosis, the present
tudy offers a new interpretative key. Our analysis reveals
hat the etiology of the amyloidosis is a third major variable,
n addition to the type of organ involved (soft tissues versus
eart) and bone tracer type. Etiologic variability must be
aken into account in future studies of scintigraphy in
ardiac amyloidosis.
What possible explanations are there for selective myo-
ardial uptake of 99mTc-DPD in TTR-related cardiac
myloidosis? Analysis of the echocardiographic and histo-
ogic characteristics of the two groups largely excludes the
ossibility of different levels of myocardial infiltration (Figs.
and 5). The affinity of all bone tracers for calcium
etermines their uptake by bone (and especially by bone
etastases and post-traumatic lesions), tumors, infected/
nflammatory tissues, and some neoplastic lesions (18). It
as been hypothesized that uptake of phosphonates in
myloidotic tissues might be explained by high calcium
oncentration in amyloid deposits (10,32,33). A model
apable of fully explaining our findings would have to
ccount for all three forms of variability (etiology, type of
rgan involved, tracer type), and in particular why 99mTc-
PD uptake is massive in myocardium of patients with
TR-related amyloidosis, absent in myocardium of AL
l Group
roup B
L CA
Patients)
Unaffected
Control Patients
(10 Patients)
p Value
(Kruskal-Wallis Test/
Contigency Tables)
3.8‡ 2.9 0.0001
4–4.05 2.7–3.5
7.6‡ 56 0.010
.8–71.3 52–60
5.4 5.4 0.0001
.2–5.5 5.0–5.7
(100%) 10 (100%) 0.0001
(0%) 0 (0%)
(0%) 0 (0%)
(0%) 0 (0%)
ntrol group.ntro
G
A
(10
3.
6
61
5
10
0
0
0atients, and present in soft tissues of both groups. No such
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Etiologic Diagnosis of Cardiac Amyloidosis September 20, 2005:1076–84odel currently exists. Onset of amyloidosis is a very
omplex process, eventually leading to tissue deposition of
myloid fibrils (34). Although amyloid fibrils share a com-
on chemical structure (i.e., serum amyloid protein) irre-
pective of etiology, some characteristics vary between
pecific etiologies (allowing differential immunostaining).
e can only speculate that 99mTc-DPD might bind to
pecific fragments of the mutated TTR protein or of the
ild-type protein (present in the senile form), and that this
henomenon occurs predominantly in the myocardium
ither because of the large amount of amyloid or some
nknown features of its spatial arrangement at this level.
It should be noted that in our study sample, 99mTc-
DP, unlike 99mTc-DPD, did not show selective myocar-
ial uptake in 11 patients with TTR-related cardiac amy-
oidosis. This finding agrees with one reported case (9), but
ontrasts with a further two (19,20) with an apparently
efinite diagnosis of TTR-related cardiac amyloidosis.
Our findings have potential clinical implications in a
linical setting, where misdiagnosis rates between hereditary
igure 3. Macroscopic/histologic findings (top) and scintigraphic image
middle) or 99mTc-methylene diphosphonate (99mTc-MDP) (bottom) as
ombined heart-liver transplantation (left) and a group B patient with mo
re apparent: 1) despite similar left ventricular (LV) thickness and amount
s characteristically strong (without bone uptake) in the patient with TTR-r
one uptake); 2) conversely, use of a different tracer (99mTc-MDP) results in
ptake) in both patients. The macrohistologic sections show pale gray-blu
taining (lower insets) shows typical green birefringence under cross-polar
gainst TTR is positive (upper inset). RV  right ventricle.TR and AL amyloidosis can be as high as 7% (7) and lhere the repercussions can be disastrous (chemotherapy
ith/without bone marrow transplantation instead of
LT). In patients with diagnosis of cardiac amyloidosis
ssociated with monoclonal gammopathy, negative 99mTc-
PD scintigraphy would reinforce a diagnostic hypothesis
f AL etiology, whereas a positive test result would direct
he diagnostic workup toward DNA analysis and immuno-
istochemistry. Also, 99mTc-DPD scintigraphy could be
sed as an orientative diagnostic step in cases of suspected
enile (wild-type TTR) cardiac amyloidosis.
tudy limitations. Considering the restricted number of
atients (especially in the AL cardiac amyloidosis subgroup),
ndependent confirmation is required on a larger study sample.
ur tertiary center included cardiology/neurology units partic-
larly active in the field of amyloidosis, and especially familial
myloidotic polyneuropathy. Therefore, the results cannot
utomatically be extended to populations with a lower preva-
ence of the disease. It should be noted that our study does not
rovide information on the rarer hereditary forms of amyloid-
sis related to mutations of apolipoprotein A, fibrinogen,
ng 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD)
acer in a group A patient with transthyretin amyloidosis who underwent
al immunoglobulin light-chain (AL) amyloidosis (right). Two paradoxes
yloidotic infiltration in the two patients, myocardial 99mTc-DPD uptake
amyloidosis and absent in the patient with AL amyloidosis (who had only
nce of visually detectable myocardial uptake (accompanied by normal bone
loid infiltrations at Azan Mallory trichrome staining, whereas Congo-red
ight microscopy. In the patient with TTR, immunohistochemical stainings usi
the tr
noclon
of am
elated
abse
e amyisozyme, or the acquired AA type.
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9mTc-DPD scintigraphic variability in cardiac amyloidosis,
highly relevant consideration for future studies. Our
nalysis indicates that 99mTc-DPD scintigraphy could offer
useful first step in the workup of differential diagnosis of
TR versus AL etiology in patients with documented
ardiac amyloidosis.
igure 4. Apical four-chamber-view echocardiograms (top row) and cr
SPECT) (bottom row) in two patients with transthyretin (TTR)-relat
entricular parietal thickness and 99mTc-3,3-diphosphono-1,2-propanodic
he interventricular septum and the lateral wall of the left ventricle at echo
PECT; (B) increased thickness of the medial portion of the interventricula
ocalized myocardial 99mTc-DPD uptake at the same level. IVS  intraven
right ventricle.
igure 5. Distribution of left ventricular (LV) mass values according
o visual scores at myocardial 99mTc-3,3-diphosphono-1,2-
ropanodicarboxylic acid scintigraphy. No relationship between the two
ariables is discernible (p  0.54 by Kruskal-Wallis test). AL 
onoclonal immunoglobulin light-chain; TTR  transthyretin.eprint requests and correspondence: Prof. Claudio Rapezzi,
stituto di Cardiologia, Policlinico S. Orsola-Malpighi, via Mas-
arenti 9, 40138 Bologna, Italy. E-mail: crapezzi@aosp.bo.it.
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